argenx NV ADR (ARGX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, argenx NV ADR (ARGX) has a cash flow conversion efficiency ratio of 0.056x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($407.80 Million) by net assets ($7.32 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ARGX net asset quality score to measure how much of total assets are equity-financed.
argenx NV ADR - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how argenx NV ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ARGX cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
argenx NV ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of argenx NV ADR ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ING Groep N.V
MX:INGN
|
N/A |
|
Constellation Software Inc.
TO:CSU
|
0.167x |
|
Hess Corporation
NYSE:HES
|
0.113x |
|
Swedbank AB (publ)
ST:SWED-A
|
0.183x |
|
Suzhou Dongshan Precision Manufacturing Co Ltd
SHE:002384
|
0.020x |
|
Ambev SA ADR
NYSE:ABEV
|
0.035x |
|
Garmin Ltd
NYSE:GRMN
|
0.058x |
|
HOLCIM NEW(U.ADR)1/5/SF2
F:HLB
|
N/A |
Annual Cash Flow Conversion Efficiency for argenx NV ADR (2011–2025)
The table below shows the annual cash flow conversion efficiency of argenx NV ADR from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see ARGX market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $7.32 Billion | $850.49 Million | 0.116x | +871.70% |
| 2024-12-31 | $5.50 Billion | $-82.75 Million | -0.015x | +85.33% |
| 2023-12-31 | $4.10 Billion | $-420.33 Million | -0.103x | +66.55% |
| 2022-12-31 | $2.81 Billion | $-862.81 Million | -0.307x | -28.06% |
| 2021-12-31 | $2.53 Billion | $-606.81 Million | -0.239x | -0.60% |
| 2020-12-31 | $1.67 Billion | $-398.46 Million | -0.238x | -285.30% |
| 2019-12-31 | $1.18 Billion | $151.63 Million | 0.128x | +228.46% |
| 2018-12-31 | $615.87 Million | $-61.59 Million | -0.100x | +5.62% |
| 2017-12-31 | $413.81 Million | $-43.84 Million | -0.106x | -163.35% |
| 2016-12-31 | $66.65 Million | $11.15 Million | 0.167x | +144.93% |
| 2015-12-31 | $40.82 Million | $-15.19 Million | -0.372x | -192.85% |
| 2014-12-31 | $50.08 Million | $-6.37 Million | -0.127x | +58.24% |
| 2013-12-31 | $29.97 Million | $-9.12 Million | -0.304x | +54.29% |
| 2012-12-31 | $16.65 Million | $-11.09 Million | -0.666x | -366.23% |
| 2011-12-31 | $27.90 Million | $-3.98 Million | -0.143x | -- |
About argenx NV ADR
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYGART and VYGART HYTRULO to treat generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgarti… Read more